Publications by authors named "I GHELERTER"
Background: An estimated 10-15% of non-small cell lung cancer (NSCLC) cases present with epidermal growth factor receptor mutation (EGFRm). While EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib have become first-line (1L) standard of care for these patients, limited chemotherapy use still occurs in real-world practice. Studies of healthcare resource use (HRU) and cost of care provide a means by which the value of various treatment regimens, healthcare efficiency, and disease burden can be assessed.
View Article and Find Full Text PDFArticle Synopsis
- This study analyzed different strategies for starting long-acting injectable (LAI) treatments for Medicaid patients with schizophrenia, focusing on their previous use of oral antipsychotics (OAPs) and related health events.
- Researchers categorized patients into four groups based on their behavior and clinical events before starting LAIs, including adherence to OAPs and number of inpatient/ER visits.
- The findings showed that strategy #1, where patients were adherent to OAPs with no inpatient/ER visits, resulted in significantly fewer hospital stays and emergency visits compared to the other strategies, indicating that early intervention with LAIs is beneficial.
Among patients with schizophrenia, nonadherence to oral atypical antipsychotics (OAAs) leads to increased risk of relapses, which entails substantial economic burden. To evaluate the impact on health care costs and relapse rates of switching patients with schizophrenia from OAAs to once-monthly paliperidone palmitate (PP1M), with subsequent transitions to once-every-3-months (PP3M) and once-every-6-months paliperidone palmitate (PP6M). A 36-month Markov model was developed from a Medicaid payer's perspective.
View Article and Find Full Text PDFObjective: Evaluate systemic therapy utilization patterns and outcomes by line of therapy among patients with advanced/recurrent endometrial cancer (EC) treated in the United States.
Methods: This retrospective observational study used the Optum Clinformatics Extended Data Mart Date of Death database (1 January 2004-31 December 2019) and included de-identified data from adult patients with advanced/recurrent EC who were treated with first-line (1L) platinum-based chemotherapy and initiated second-line (2L) anti-neoplastic therapy. The index date was the date of 1L therapy initiation.
Background: Daratumumab was approved for multiple myeloma (MM) in 2015. While its safety and efficacy are well documented, there is limited real-world information on its use and outcomes in patients of different races.
Methods: We conducted a retrospective chart review of adult patients with MM initiating daratumumab in any line of therapy (LOT) between November 2015 and May 2020.